Jazz Pharmaceuticals Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Jazz Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Jazz Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Jazz Pharmaceuticals.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced its quarterly earnings data on Tuesday, August, 3rd. The specialty pharmaceutical company reported $3.90 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $3.08 by $0.82. The specialty pharmaceutical company earned $751.81 million during the quarter, compared to analyst estimates of $743.19 million. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 22.00% and a net margin of 1.53%.
View Jazz Pharmaceuticals' earnings history.

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, JAZZ shares have increased by 19.1% and is now trading at $128.64.
View which stocks have been most impacted by COVID-19.

Jazz Pharmaceuticals updated its FY 2021 earnings guidance on Tuesday, August, 17th. The company provided earnings per share (EPS) guidance of $13.400-$14.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.450. The company issued revenue guidance of $3.02 billion-$3.18 billion, compared to the consensus revenue estimate of $3.11 billion.

13 brokerages have issued 12 month price targets for Jazz Pharmaceuticals' stock. Their forecasts range from $175.00 to $250.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $207.92 in the next twelve months. This suggests a possible upside of 61.6% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals or view top-rated stocks among Wall Street analysts.

60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Omeros (OMER).
View all of JAZZ's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Jazz Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.08%), Vanguard Group Inc. (8.97%), FMR LLC (5.63%), Jefferies Group LLC (0.00%), JPMorgan Chase & Co. (4.72%) and State Street Corp (3.92%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Bruce C Cozadd, Elmar Schnee, Finbar Larkin, James E Flynn, Kenneth W O'keefe, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul L Berns and Seamus Mulligan.
View institutional ownership trends for Jazz Pharmaceuticals.

JAZZ stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, HBK Investments L P, HBK Investments L P, AQR Capital Management LLC, Goldman Sachs Group Inc., LSV Asset Management, and FMR LLC. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Elmar Schnee, Finbar Larkin, Patricia Carr, Patrick G Enright, and Paul L Berns.
View insider buying and selling activity for Jazz Pharmaceuticals or view top insider-selling stocks.

JAZZ stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Polaris Capital Management LLC, JPMorgan Chase & Co., Victory Capital Management Inc., Vanguard Group Inc., Macquarie Group Ltd., Morgan Stanley, and Morgan Stanley. Company insiders that have bought Jazz Pharmaceuticals stock in the last two years include James E Flynn, and Seamus Mulligan.
View insider buying and selling activity for Jazz Pharmaceuticals or or view top insider-buying stocks.

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JAZZ stock can currently be purchased for approximately $128.64.

Jazz Pharmaceuticals has a market capitalization of $7.89 billion and generates $2.36 billion in revenue each year. The specialty pharmaceutical company earns $238.62 million in net income (profit) each year or $10.77 on an earnings per share basis.

Jazz Pharmaceuticals employs 1,940 workers across the globe.

The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.

Jazz Pharmaceuticals was founded in 2003.

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

Jazz Pharmaceuticals is headquartered at FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04.

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at (531) 634-7800 or via email at [email protected].